Literature DB >> 10697724

Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets.

E J Knust1, K Dutschka, R Weinreich.   

Abstract

The 4.15-d radionuclide 124I is produced via the nuclear reaction 124Te(d, 2n) 124I by irradiation of 96% enriched 124TeO2 with 14 MeV deuterons, followed by thermodistillation. In order to minimise the loss of 124I, the quartz distillation tube was fitted to a stainless steel helix capillary trap directly behind the end of the furnace. Using this device, distillation yields of more than 80% were routinely obtained, and the activity was concentrated in markedly less than 100 microL solution. The 124I produced by this method proved to be useful for labelling proteins and IUdR.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697724     DOI: 10.1016/s0969-8043(99)00127-x

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  10 in total

1.  (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution.

Authors:  Andreas Bockisch; Lutz Freudenberg; Sandra Rosenbaum; Walter Jentzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

2.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

Review 3.  The production of [124I]iodine and [86Y]yttrium.

Authors:  Jochen Schmitz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 4.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

5.  Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons.

Authors:  Lutz Stefan Freudenberg; Walter Jentzen; Thorsten Petrich; Cornelia Frömke; Robert J Marlowe; Till Heusner; Wolfgang Brandau; Wolfram H Knapp; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-27       Impact factor: 9.236

6.  Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.

Authors:  Walter Jentzen; Reiner Weise; Jürgen Kupferschläger; Lutz Freudenberg; Wolfgang Brandau; Ronald Bares; Wolfgang Burchert; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

7.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

8.  Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET.

Authors:  Lutz S Freudenberg; Walter Jentzen; Stefan P Müller; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-20       Impact factor: 10.057

Review 9.  Iodine-124: a promising positron emitter for organic PET chemistry.

Authors:  Lena Koehler; Katherine Gagnon; Steve McQuarrie; Frank Wuest
Journal:  Molecules       Date:  2010-04-13       Impact factor: 4.411

Review 10.  Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.

Authors:  Krishan Kumar; Arijit Ghosh
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.